Navigation Links
Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others
Date:7/31/2009

Bethesda, MD (August 1, 2009) The antidiabetic medication metformin is associated with a reduced risk of pancreatic cancer in diabetics, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. However, other commonly used therapies, such as insulin or insulin secretagogues, may be associated with increased risk for the deadly disease.

"The current study demonstrated a robust protective effect of metformin against pancreatic cancer in diabetes. Our major observations were that diabetics who ever used metformin, especially those with greater than five years of use, had a reduced risk of pancreatic cancer compared to diabetics who had not taken these drugs," said Donghui Li, PhD, of The University of Texas M. D. Anderson Cancer Center and lead author of the study. "This adds evidence to previous study findings indicating that antidiabetic therapy can affect the development of cancer."

Study authors found that diabetics who took metformin had a 60 percent lower risk of pancreatic cancer, compared with those that had not taken metformin. This difference remained statistically significant when the analysis was restricted to patients with duration of diabetes greater than two years or those who never used insulin. Other diabetes-associated factors, including history of smoking, overweight or obesity, and glycemic control, did not have a significant effect on the relationship between metformin use and pancreatic cancer risk. In contrast, diabetics who had taken insulin or insulin secretagogues had 4.99- and 2.52-fold increased risks for pancreatic cancer, respectively, compared with never-users.

This hospital-based, case-control study, conducted at M. D. Anderson from 2004 through 2008, involved 973 patients with pancreatic adenocarcinoma (including 259 diabetics) and 863 controls (including 109 diabetics). Pancreatic cancer risk was estimated using unconditional logistic regression analysis.

"Further study is needed in other study populations to confirm or refute a possible role of antidiabetic therapy in pancreatic cancer. Since pancreatic cancer is a rapidly fatal, but a relatively uncommon cancer, epidemiological research on this disease is challenging," Dr. Li added. "If the finding that metformin is protective against pancreatic cancer is confirmed, metformin may offer a tool for the primary prevention of pancreatic cancer among people with type II diabetes."

Pancreatic cancer is the fourth leading cause of death from cancer for both men and women in the U.S. The association of type II diabetes mellitus and pancreatic cancer is complex. On one hand, type II diabetes can occur as a consequence of pancreatic cancer. On the other hand, there is accumulating evidence to strongly support a significant role of type II diabetes in pancreatic carcinogenesis.


'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Smoking increases potential for metastatic pancreatic cancer
2. New drug candidate prolongs the lives of pancreatic cancer patients
3. Dietary fat linked to pancreatic cancer
4. Eating Animal Fat May Lead to Pancreatic Cancer
5. Obesity While Young Boosts Pancreatic Cancer Risk
6. Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer
7. Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
8. Epeius Biotechnologies Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
9. Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
10. Mayo Clinic finds new pathology tests double sensitivity to detect bile duct and pancreatic cancers
11. $18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an industrial ... recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by Xlibris ... anatomy , trigger points and referral pain patterns . , In this ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based ... velvet, announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... and VANCOUVER, British Columbia ... OGXI ) today announced its year end ... In January 2017, OncoGenex, and Achieve Life Science, ... they have entered into a definitive merger agreement under ... Upon completion of the proposed merger, Achieve,s stockholders are ...
Breaking Medicine Technology: